Issue Date: March 12, 2018 | Web Date: March 9, 2018
Interest in targeted protein degraders continues in new partnership between Celgene and Vividion
In another sign of growing pharmaceutical industry interest in targeted protein degradation, Celgene will pay Vividion Therapeutics $101 million in a four-year pact to develop small-molecule drugs for cancer, inflammation, and neurodegenerative diseases.
Vividion was founded in 2014 and raised its first $50 million last year. The start-up’s technology, now being used to develop protein degraders, is based on the work of three Scripps Research Institute . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society